Medivir Announces Departure of Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that John Öhd, Chief Medical Officer at Medivir, has decided to leave the company. He will remain with Medivir until July 15, 2018.

“Over the last four years, John has been responsible for shaping the clinical pipeline we have today and recruiting the clinical development team that is advancing our three innovative drugs in the clinic and with an additional clinical study start expected in the near future. We wish John all the best in his new position, and thank him for his many significant contributions to the company”, said Christine Lind, CEO of Medivir.

A recruitment process to find a new Chief Medical Officer will be initiated.

For more information please contact:
Christine Lind, CEO Medivir AB, mobile +46 (0) 72 710 2205

This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 22.00 CET on March 14, 2018.

About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Tags:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe

Documents & Links